Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis

Leukemia

Volumn 30, Issue 2, 2016, Pages 331-336

  Solomon, B M ^a,b   Chaffee, K G ^c   Moreira, J ^d   Schwager, S M ^c   Cerhan, J R ^c   Call, T G ^c   Kay, N E ^c   Slager, S L ^c   Shanafelt, T D ^c  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Avera Medical Group Oncology and Hematology   (United States)

^c MAYO CLINIC   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MENINGIOMA; MONOCLONAL B CELL LYMPHOCYTOSIS; NECK CANCER; NON HEMATOLOGIC CANCER; OVARY CANCER; PANCREAS CANCER; PERIPHERAL NERVE TUMOR; PERITONEUM CANCER; PRIORITY JOURNAL; SECOND CANCER; STOMACH CANCER; THYROID CANCER; TONGUE CANCER; TONSIL CANCER; URETER CANCER; ADOLESCENT; B LYMPHOCYTE; COMPLICATION; LYMPHOCYTOSIS; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODEL; RISK; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 84959322929     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.235     Document Type: Article

References (33)

1. Call TG, Phyliky RL, Noel P, Habermann TM, Beard CM, O'Fallon WM, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc 1994; 69: 323-328.
2. Hisada M, Biggar RJ, Greene MH, Fraumeni Jr JF, Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 1979-1981.
3. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010; 28: 4935-4944.
4. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009; 27: 904-910.
5. Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232: 267-269.
6. Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007; 139: 398-404.
7. Schollkopf C, Rosendahl D, Rostgaard K, Pipper C, Hjalgrim H. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 2007; 121: 151-156.
8. Solomon BM, Rabe KG, Slager SL, Brewer JD, Cerhan JR, Shanafelt TD. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol 2013; 31: 930-937.
9. Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005; 130: 325-332.
10. Fazi C, Scarfo L, Pecciarini L, Cottini F, Dagklis A, Janus A, et al. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 2011; 118: 6618-6625.
11. Ghia P, Prato G, Scielzo C, Stella S, Geuna M, Guida G, et al. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004; 103: 2337-2342.
12. Rawstron AC, Bennett FL, O'Connor SJ, Kwok M, Fenton JA, Plummer M, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359: 575-583.
13. Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA, et al. Monoclonal B lymphocytes with the characteristics of 'indolent' chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002; 100: 635-639.
14. Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 2010; 24: 512-520.
15. Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Maddocks K, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 3959-3963.
16. Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, et al. Infectious complications among individuals with clinical Monoclonal B-cell Lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia 2012; 27: 136-141.
17. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008; 49: 49-56.
18. Cerhan JR, Fredericksen ZS, Wang AH, Habermann TM, Kay NE, Macon WR, et al. Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. Int J Mol Epidemiol Genet 2011; 2: 95-113.
19. Gooley T, Leisenring W, Crowely J, Storer B. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
20. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
21. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
22. Brewer JD, Shanafelt TD, Otley CC, Roenigk RK, Cerhan JR, Kay NE, et al. Chronic lymphocytic leukemia decreases survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER Population-Based Study. J Clin Oncol 2012; 30: 843-849.
23. Moyer VA. Screening for lung cancer: U.S. Preventative Services Task Force Recommendation Statement. Ann Intern Med 2014; 160: 330-338.
24. Force USPST. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151: 716-726, W-236.
25. Force USPST. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627-637.
26. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
27. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero D, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
28. Scarfo L, Fazi C, Ghia P. MBL versus CLL: how important is the distinction?. Hematol Oncol Clin North Am 2013; 27: 251-265.
29. Molica S, Mauro FR, Giannarelli D, Lauria F, Cortelezzi A, Brugiatelli M, et al. Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica 2011; 96: 277-283.
30. Shanafelt TD, Kay NE, Jenkins G, Call TG, Zent CS, Jelinek DF, et al. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 2009; 113: 4188-4196.
31. Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Schwager SM, et al. Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population. Leukemia 2012; 26: 373-376.
32. Mansfield AS, Rabe KG, Slager SL, Schwager SM, Call TG, Brewer JD, et al. Skin cancer surveillance and malignancies of the skin in a community-Dwelling cohort of patients with newly diagnosed chronic lymphocytic Leukemia. J Oncol Pract 2013; 10: e1-E4.
33. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis 2013; 58: e44-100.